1. Changes in the tumour microenvironment mark the transition from serous borderline tumour to low‐grade serous carcinoma.
- Author
-
Vallejos, Rodrigo, Zhantuyakova, Almira, Negri, Gian Luca, Martin, Spencer D, Spencer, Sandra E, Thornton, Shelby, Leung, Samuel, Lynch, Branden, Qin, Yimei, Chow, Christine, Liang, Brooke, Zdravko, Sabrina, Douglas, J Maxwell, Milne, Katy, Mateyko, Bridget, Nelson, Brad H, Howitt, Brooke E, Kommoss, Felix KF, Horn, Lars‐Christian, and Hoang, Lien
- Subjects
REGULATORY T cells ,OVARIAN tumors ,TUMOR microenvironment ,BIOMARKERS ,T cells - Abstract
Low‐grade serous ovarian carcinoma (LGSC) is a rare and lethal subtype of ovarian cancer. LGSC is pathologically, biologically, and clinically distinct from the more common high‐grade serous ovarian carcinoma (HGSC). LGSC arises from serous borderline ovarian tumours (SBTs). The mechanism of transformation for SBTs to LGSC remains poorly understood. To better understand the biology of LGSC, we performed whole proteome profiling of formalin‐fixed, paraffin‐embedded tissue blocks of LGSC (n = 11), HGSC (n = 19), and SBTs (n = 26). We identified that the whole proteome is able to distinguish between histotypes of the ovarian epithelial tumours. Proteins associated with the tumour microenvironment were differentially expressed between LGSC and SBTs. Fibroblast activation protein (FAP), a protein expressed in cancer‐associated fibroblasts, is the most differentially abundant protein in LGSC compared with SBT. Multiplex immunohistochemistry (IHC) for immune markers (CD20, CD79a, CD3, CD8, and CD68) was performed to determine the presence of B cells, T cells, and macrophages. The LGSC FAP+ stroma was associated with greater abundance of Tregs and M2 macrophages, features not present in SBTs. Our proteomics cohort reveals that there are changes in the tumour microenvironment in LGSC compared with its putative precursor lesion, SBT. These changes suggest that the tumour microenvironment provides a supportive environment for LGSC tumourigenesis and progression. Thus, targeting the tumour microenvironment of LGSC may be a viable therapeutic strategy. © 2024 The Pathological Society of Great Britain and Ireland. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF